Table 1.
Patient and Tumor Characteristics (n=34)
| Variable | n(%), Median(Range) |
|---|---|
| Median age at AI initiation | 53 years (35–74) |
| Performance status | |
| 0 | 2 (6%) |
| 1 | 30 (88%) |
| 2 | 1 (3%) |
| 3 | 1 (3%) |
| Ethnicity | |
| Caucasian | 27 (79%) |
| Hispanic | 4 (12%) |
| African American | 2 (6%) |
| Asian/Indian | 1 (3%) |
| Postmenopausal status | 31 (91%) |
| Median body mass index | 28 kg/m2 (16–52) |
| Number of comorbidities | |
| 0–1 | 14 (41%) |
| 2–3 | 18 (53%) |
| 4–5 | 2 (6%) |
| FIGO stage at diagnosis | |
| I | 11 (32%) |
| II | 4 (12%) |
| III | 3 (9%) |
| IV | 16 (47%) |
| Sites of metastases at time of AI initiation | |
| Lung | 30 (88%) |
| Lung as only site of metastases | 6 (18%) |
| Pelvis | 19 (56%) |
| Bone | 6 (18%) |
| Liver | 5 (15%) |
| Brain | 1 (3%) |
| Tumor volume at time of AI initiation | |
| Low | 19 (56%) |
| High | 15 (44%) |
| Histologic grade | |
| Low | 5 (15%) |
| High | 29 (85%) |
| Hormone receptor status | |
| ER | n=31 |
| Positive | 22 (71%) |
| Negative | 9 (29%) |
| PR | n=20 |
| Positive | 10 (50%) |
| Negative | 10 (50%) |
| ER and PR | n=20 |
| Positive | 9 (45%) |
| Negative | 5 (25%) |
Abbreviations: AI, Aromatase inhibitor; FIGO, International Federation of Gynecology and Obstetrics; ER, estrogen receptor; PR, progesterone receptor